Home » Business News » 2012 » April » April 2, 2012

MorphoSys to Start Share Buy-Back Program

April 2, 2012 - Martinsried, Germany And Munich, Germany

MorphoSys AG /MorphoSys to Start Share Buy-Back Program.

Processed and transmitted by Thomson Reuters ONE. The issuer is solelyresponsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announcedtoday thedecision to repurchase its own shares on the stock market. Followingapproval bythe Company's Supervisory Board, the Board of Management of MorphoSysAG hasresolved to acquire up to 100,000 MorphoSys shares over the stock marketduringthe time period from April 1, 2012 to April 30, 2012. The shares will beused toimplement the Company's long-term incentive program 2012 for itsmanagement.

The relevant conditions of the shareholders' resolutions passed in theordinaryshareholders' meeting 2011 of MorphoSys AG on the authorization toacquire andto use its own shares shall apply. The purchase price paid per share maynot bemore than 10 % higher or 20 % lower than the Company's share pricedetermined bythe opening auction in the Xetra trading system on the day of trading.On thebasis of the current share price (status: March 30, 2012), this wouldamount toaround EUR 1.76 million or up to 0.4% of the share capital.

The buy-back is to be handled independently of and uninfluenced by theCompanythrough an appointed bank in compliance with the safe-harbor provisions.

MorphoSys will provide regular information on the progress of the sharebuy-backprogram on the Company's website

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.TheCompany's AbD Serotec unit uses HuCAL and other technologies to generatesuperior monoclonal antibodies for research and diagnostic applications.Through its own development efforts and successful partnerships in thepharmaceutical industry, MorphoSys has built a therapeutic pipeline of morethan70 human antibody drug candidates for the treatment of cancer, rheumatoidarthritis, and Alzheimer's disease, to name just a few. With its ongoingcommitment to new antibody technology and drug development, MorphoSys isfocusedon engineering the medicines of tomorrow. MorphoSys is listed on theFrankfurtStock Exchange under the symbol MOR. For regular updates about MorphoSys,visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,RapMAT® and arYla® areregistered trademarks of MorphoSys AG. Ylanthia® and 100billion highpotentialsTM are trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, asubsidiaryof MorphoSys AG.

This communication contains certain forward-looking statementsconcerning theMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from theCompany'sassumptions, actual results and actions may differ from thoseanticipated.MorphoSys does not intend to update any of these forward-lookingstatements asfar as the wording of the relevant press release is concerned.

Media Release:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE[HUG#1599183]

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact


Comment on this story